MiR-181b is a possible non-invasive molecular marker for the aggressiveness of non- small cell Lung cancer

Lung cancer is considered the foremost predominant cancer all over the world. MIR-181bis involved in multiple critical roles in malignant tumors. Its function in non-small cell lung cancer (NSCLC) remains vague. The current study aims to assess the function of MIR-181b in NSCLC and the possibility of its use as a molecular marker for NSCLC aggressiveness. This study included 76 NSCLC patients with early or locally advanced tumors and underwent surgical resection. MIR-181bexpression in NSCLC tissues, H23, and H522 cells, and their adjacent normal lung parenchyma was quantified by QR-PCR. The H23 and H522 cell lines were transfected with MIR-181b. We analyzed the bioinformatics and utilized western blot and luciferase reporter studies to assess the invasiveness and metastases of MIR-181b transfected cell lines. Results: MIR-181b was significantly downregulated in NSCLC tissues and cell lines. Downregulation of MIR181bwas found to prevent invasion and metastases in NSCLC cells by triggering the High Mobility Group Box-1 (HMGB1). In NSCLC patients, the downregulation of MIR-181bwas significantly associated with adverse clinical and pathological features in addition to short disease and overall survival. MIR-181b was downregulated in NSCLC. Its downregulation was associated with invasiveness and metastases by targetingHMGB1 in cell lines. In NSCLC patients, MIR181bdownregulation was related to adverse clinical and pathological features and short survival.